Healthcare
HEALWELL presents AI-enabled clinical evidence projects
HEALWELL AI and partners are presenting studies using AI and real-world evidence, including a tool designed to identify potential cardiac amyloidosis patients in clinics.
HEALWELL AI and collaborators are presenting 12 scientific abstracts and presentations at eight international conferences. The company says eight are ethics-approved real-world-evidence studies conducted with seven life-sciences partners, alongside four HEALWELL-led presentations. One highlighted project, AccelerATTR, uses AI-enabled identification of potential transthyretin amyloidosis patients in cardiac clinics. The program illustrates how healthcare AI can be applied to identify patients who may otherwise be missed in routine specialty care. The company’s conference activity also covers treatment persistence in inflammatory bowel disease and clinical characteristics of dermatological conditions, showing a broader focus on real-world evidence and clinical data analysis. The source does not provide outcome results for AccelerATTR or establish that the system has changed clinical practice. Its importance is therefore linked to the scale of the evidence-generation program and the involvement of multiple life-sciences partners. Presenting findings at specialist medical conferences can help expose AI-supported patient identification and evidence-generation methods to clinicians and researchers for review.
Original source: Yahoo Finance